I det pivotale to- års studie hos postmenopausale kvinder med osteoporose (BM 16550) var sikkerheden af i. v. behandling med Bonviva 3 mg hver 3 måned og oral ibandronsyre 2, 5 mg daglig den samme.
In the pivotal two-year study in postmenopausal women with osteoporosis (BM16550), the overall safety of intravenous injection of Bonviva 3 mg every 3 months and oral ibandronic acid 2.5 mg daily were shown to be similar.